2 Soaring Stocks With More Upside Potential to Buy and Hold
SoFi is finally showing that its business model can be profitable, and the stock still has plenty of upside.
10 stocks we like better than Summit Therapeutics ›
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. Some companies don't have much growth fuel left in the tank after a nice run, while others still boast significant upside potential after juicy gains. It's best to stay away from the former, but the investing wisdom according to which we should "buy low" still applies to the latter.
Let's consider two companies that have performed exceptionally well recently but still have excellent long-term prospects: Summit Therapeutics (NASDAQ: SMMT) and SoFi Technologies (NASDAQ: SOFI).
Summit Therapeutics has been on a tear over the past two years thanks to progress with its leading pipeline candidate, ivonescimab. The biotech licensed out this investigational cancer medicine from China-based Akeso Biopharma. Summit Therapeutics owns the rights to the medicine in most regions, including the most lucrative ones for biotech companies: North America and Europe.
Last year, ivonescimab produced excellent results in a phase 3 study in China (where it is approved) for patients with non-small cell lung cancer (NSCLC). The study pitted ivonescimab against the market leader, Merck's Keytruda. Since Keytruda is the world's best-selling drug and NSCLC is one of its most important markets, ivonescimab's potential looks massive.
Although Summit Therapeutics' shares have already soared as a result, the company's future still looks bright. Here are two reasons why. First, Summit Therapeutics is conducting late-stage studies for ivonescimab in the U.S. and is expected to release key data readouts in the next couple of years, which could significantly affect its stock price.
Second, even though NSCLC is going to be a crucial market for ivonescimab's success, the medicine looks like a potential pipeline in a drug. It is being tested across many different types of cancers. Ivonescimab could rack up approvals and label expansions for years to come.
Summit may encounter clinical or regulatory setbacks. It's good to keep that in mind before initiating a position. But the stock could deliver monster results in the next five years if its master plan comes to fruition.
Shares of SoFi -- an online bank -- have more than doubled over the trailing 12-month period. That's an impressive achievement, especially considering the somewhat challenging economic conditions we face. Many fear that President Donald Trump's trade agenda could lead to inflation or a recession. That would affect consumer behavior, resulting in slower loan demand and increased loan defaults, all of which would be detrimental to SoFi.
Despite the risk, the market has been impressed with SoFi's financial results. In the first quarter, the company's revenue increased by 20% year over year to $771.8 million. SoFi's net income dropped by 19% year over year to $71.1 million, but it was well above management's own guidance. SoFi's results were strong across the board, with the company's membership and products also moving in the right direction. That will remain the blueprint for long-term success for SoFi.
First, the number of members on its platform should continue growing. SoFi is an entirely online bank with no physical locations (which allows the company to save on overhead costs). Digital banking is the future, as evidenced by the fact that younger generations are more likely to engage in it than older ones. Legacy banking institutions have adapted, but SoFi is also popular -- it ended Q1 with a record 10.9 million members, up 34% compared to the year-ago period.
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its existing users. The company recorded 15.9 million products in Q1. That means it had, on average, about 1.5 products per member, despite offering many more than that amount.
Third, SoFi has consistently expanded its pool of offerings, which provides other growth opportunities and makes its platform even more attractive to consumers. Although the stock could suffer in a recession, SoFi is well-positioned to perform well over the long run. So, even after its terrific performance in the past year, the stock remains a buy.
Before you buy stock in Summit Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!*
Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 30, 2025
Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Summit Therapeutics. The Motley Fool has a disclosure policy.
2 Soaring Stocks With More Upside Potential to Buy and Hold was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
China's Zeekr says it did not sell or register zero-mileage used cars
BEIJING (Reuters) -Chinese automotive firm Zeekr said in a statement on Sunday that used cars described in media reports as having zero mileage were exhibition cars that were insured, but it did not sell or register them. The company has set up a team to investigate and make improvements, Zeekr said, adding that it opposed the sale of zero-mileage used cars. On Saturday, Reuters and state-backed China Securities Journal newspaper had reported that Zeekr had insured cars before selling them to buyers, inflating sales.
Yahoo
18 minutes ago
- Yahoo
Celebrus Technologies plc's (LON:CLBS) Stock Is Going Strong: Is the Market Following Fundamentals?
Celebrus Technologies' (LON:CLBS) stock is up by a considerable 22% over the past month. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. In this article, we decided to focus on Celebrus Technologies' ROE. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In simpler terms, it measures the profitability of a company in relation to shareholder's equity. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. How To Calculate Return On Equity? The formula for return on equity is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Celebrus Technologies is: 15% = UK£6.4m ÷ UK£43m (Based on the trailing twelve months to March 2025). The 'return' is the amount earned after tax over the last twelve months. Another way to think of that is that for every £1 worth of equity, the company was able to earn £0.15 in profit. Check out our latest analysis for Celebrus Technologies Why Is ROE Important For Earnings Growth? We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes. Celebrus Technologies' Earnings Growth And 15% ROE To begin with, Celebrus Technologies seems to have a respectable ROE. Yet, the fact that the company's ROE is lower than the industry average of 20% does temper our expectations. Celebrus Technologies was still able to see a decent net income growth of 13% over the past five years. We reckon that there could be other factors at play here. Such as - high earnings retention or an efficient management in place. However, not to forget, the company does have a decent ROE to begin with, just that it is lower than the industry average. So this also does lend some color to the fairly high earnings growth seen by the company. As a next step, we compared Celebrus Technologies' net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 10.0%. Earnings growth is an important metric to consider when valuing a stock. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. Has the market priced in the future outlook for CLBS? You can find out in our latest intrinsic value infographic research report. Is Celebrus Technologies Making Efficient Use Of Its Profits? Celebrus Technologies has a three-year median payout ratio of 33%, which implies that it retains the remaining 67% of its profits. This suggests that its dividend is well covered, and given the decent growth seen by the company, it looks like management is reinvesting its earnings efficiently. Moreover, Celebrus Technologies is determined to keep sharing its profits with shareholders which we infer from its long history of paying a dividend for at least ten years. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 35%. However, Celebrus Technologies' future ROE is expected to decline to 10% despite there being not much change anticipated in the company's payout ratio. Summary On the whole, we feel that Celebrus Technologies' performance has been quite good. Specifically, we like that it has been reinvesting a high portion of its profits at a moderate rate of return, resulting in earnings expansion. With that said, on studying the latest analyst forecasts, we found that while the company has seen growth in its past earnings, analysts expect its future earnings to shrink. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
18 minutes ago
- Yahoo
Best CD rates today, July 20, 2025 (lock in up to 5.5% APY)
Find out how much you could earn by locking in a high CD rate today. A certificate of deposit (CD) allows you to lock in a competitive rate on your savings and help your balance grow. However, rates vary widely across financial institutions, so it's important to ensure you're getting the best rate possible when shopping around for a CD. The following is a breakdown of CD rates today and where to find the best offers. Overview of CD rates today Historically, longer-term CDs offered higher interest rates than shorter-term CDs. Generally, this is because banks would pay better rates to encourage savers to keep their money on deposit longer. However, in today's economic climate, the opposite is true. As of July 20, 2025, the highest CD rate is 5.5% APY, offered by Gainbridge® on its 5-year CD. There is a $1000 minimum opening deposit required. This embedded content is not available in your region. How much interest can I earn with a CD? The amount of interest you can earn from a CD depends on the annual percentage rate (APY). This is a measure of your total earnings after one year when considering the base interest rate and how often interest compounds (CD interest typically compounds daily or monthly). Say you invest $1,000 in a one-year CD with 1.81% APY, and interest compounds monthly. At the end of that year, your balance would grow to $1,018.25 — your initial $1,000 deposit, plus $18.25 in interest. Now let's say you choose a one-year CD that offers 4% APY instead. In this case, your balance would grow to $1,040.74 over the same period, which includes $40.74 in interest. The more you deposit in a CD, the more you stand to earn. If we took our same example of a one-year CD at 4% APY, but deposit $10,000, your total balance when the CD matures would be $10,407.42, meaning you'd earn $407.42 in interest. Read more: What is a good CD rate? Types of CDs When choosing a CD, the interest rate is usually top of mind. However, the rate isn't the only factor you should consider. There are several types of CDs that offer different benefits, though you may need to accept a slightly lower interest rate in exchange for more flexibility. Here's a look at some of the common types of CDs you can consider beyond traditional CDs: Bump-up CD: This type of CD allows you to request a higher interest rate if your bank's rates go up during the account's term. However, you're usually allowed to "bump up" your rate just once. No-penalty CD: Also known as a liquid CD, type of CD gives you the option to withdraw your funds before maturity without paying a penalty. Jumbo CD: These CDs require a higher minimum deposit (usually $100,000 or more), and often offer higher interest rate in return. In today's CD rate environment, however, the difference between traditional and jumbo CD rates may not be much. Brokered CD: As the name suggests, these CDs are purchased through a brokerage rather than directly from a bank. Brokered CDs can sometimes offer higher rates or more flexible terms, but they also carry more risk and might not be FDIC-insured. This embedded content is not available in your region.
